Micron Secures $43M for Measles, Rubella & Needle-Free Infant Vaccines
Micron Biomedical received a $7.5 million grant from the Bill & Melinda Gates Foundation, bringing total funding from the...
Micron Biomedical received a $7.5 million grant from the Bill & Melinda Gates Foundation, bringing total funding from the...
Solid Biosciences has received FDA clearance for its Investigational New Drug (IND) application for SGT-212, a gene therapy designed...
Sana Biotechnology announced positive initial results from a first-in-human study involving a patient with type 1 diabetes. The study,...
A 36-month study using data from the American Academy of Ophthalmology IRIS® Registry demonstrated that Sight Sciences’ OMNI® Surgical...
Immix Biopharma has completed the safety run-in portion of its U.S. Phase 1b NEXICART-2 study for NXC-201, a CAR-T...
Cyclarity Therapeutics has received regulatory approval to commence its first-in-human clinical trial for UDP-003 at CMAX in Australia, partnered...
Biomea Fusion announced positive preclinical data for icovamenib combined with semaglutide, a GLP-1 receptor agonist, in treating type 2...
Grove AI, a clinical trial management company, secured $4.9 million in seed funding led by A•, with participation from...
The global conventional and alternative pain treatment market, valued at $96.2 billion in 2024, is projected to reach $144.2...
Carmell Corporation (Nasdaq: CTCX) recently closed a private placement, raising $1.85 million by issuing 8,065,210 shares of common stock...